Medgadget.com | Precision Oncology: Interview with Presage Biosciences Founder Dr. James Olson Medgadget.com Dr. Olson: The trial is enrolling patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously treated with one or more agents in the R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, ... |
